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Abstract. After 25 years, evaluation of minimal residual disease (MRD) in follicular lymphoma 
(FL) has become a standardized technique frequently integrated into clinical trials for its 
consistent and independent prognostic significance. Achievement of a sustained MRD negativity 
is a marker of treatment sensibility that has been associated with excellent clinical outcome in 
terms of clinical response and progression-free survival, independently from the employed 
therapy. However, no survival advantages has been reported for MRD negative patients and 
despite the compelling results of clinical trials, MRD evaluation has currently no role in clinical 
practice. Ongoing clinical trials will help in clarifying the potential setting in which MRD 
monitoring may have a routine clinical application i.e. allowing de-escalation of standard 
maintenance therapy in very low risk patients. In this review the clinical implications of MRD 
monitoring in Rituximab-era are discussed in light of the current treatment paradigms most 
aimed at reducing toxicities, and the response definition that now routinely integrates PET scan. 
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Introduction. Follicular lymphoma (FL) is the 
most common indolent non-Hodgkin lymphoma 
(NHL), accounting for 20-30% of all NHL in 
Western countries.
1
 It is characterized by a chronic 
course, with a projected survival of more than 18 
years in the modern chemo-immunotherapy era.
2
 
While some patients with limited stage disease 
may be cured, those presenting with advance stage 
or relapsing after local radiotherapy are generally 
considered not curable with standard treatments.
1
 
Early studies have shown that deferring treatment 
in asymptomatic patients with low tumor burden is 
not associated to a worse survival and, in many 
cases, the disease can remain stable for several 
years.
3,4
 The usefulness of watchful waiting has 
been later on confirmed in the Rituximab era.
5
 
Thus only patients bearing a high tumor burden 
disease and/or symptomatic are currently treated 
with chemo-immunotherapy. Standard, first line 
treatment includes the use of Rituximab plus 
chemotherapy with an expected overall response 
rates of more than 90% and complete remissions 
in the range of 25–70% with median progression-
free survival (PFS) exceeding 4 years.
6
 A two 
years maintenance with Rituximab in responders 
results in significant prolongation of PFS, but not 
overall survival (OS).
7,8
 Therefore, despite the 
excellent improvement gained by chemo-
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immunotherapy, the majority of the patients 
eventually progress or relapse. 
Several factors have been identified as of key 
importance in predicting PFS and OS, among 
those the quality of first line response have been 
shown to be remarkably associated to survival 
outcomes.
9
 Traditionally, response evaluation in 
FL has been made with the use of contrast 
enhanced computed tomography (CT)-scan and 
bone marrow biopsy (BMB) along with standard 
laboratory tests and clinical parameters.
10,11
 
Immunohistochemical staining of BMB is the 
standard technique to assess lymphoma 
infiltration, but more sensitive assays have been 
developed to detect subclinical involvement. The 
presence of a hybrid BCL2/IGH gene in 80-90% 
of FL has spurred the interest in applying 
polymerase chain reaction (PCR) techniques to 
test the bone marrow (BM) and peripheral blood 
(PB) of patients before and after treatment.
12,13
 In 
the current review we will discuss the 
methodological aspects of molecular monitoring 
and its clinical significance in the modern chemo-
immunotherapy era. 
 
Technical Aspects. The genetic hallmark of FL is 
the t(14;18)(q32;q21) translocation that leads to 
deregulated expression of the anti-apoptotic gene 
BCL2 in tumor cells, thus allowing for the 
acquisition of secondary chromosomal alterations 
in the germinal center environment, where the 
most non-neoplastic B cells undergo apoptosis.
14
 
The resulting hybrid gene BCL2/IGH is highly 
attractive for PCR based assays as it is a disease 
specific clonal sequence directly linked to FL 
pathogenesis and thus represents a highly stable 
marker. Five different clusters of BCL2/IGH 
rearrangements occur: the major breakpoint region 
(MBR), the minor clustering region (mcr), the 
intermediate cluster region (ICR), the 3′-BCL-2 
region and the 5′-mcr region (Figure 1).15 To date, 
the molecular detection of minimal residual 
disease (MRD) has been almost entirely based 
only on the study of MBR and mcr which account 
for about 50 and 10% of all BCL2 rearrangements, 
respectively.
15
 Qualitative (nested) PCR (nPCR) 
has been widely used in molecular testing FL 
patients and proved as a highly reproducible 
method with an excellent sensitivity level able to 
detect 1 neoplastic cell in about a hundred 
thousand normal cells (1x10
-5
).
16
 The advent of 
TaqMan-based approaches allowed the 
introduction of quantitative PCR methods i.e. real-
time quantitative PCR (RQ-PCR), a significant 
step forward from the mere presence or absence of 
a BCL2/IGH rearrangement.
17,18
 This latter 
technique made possible the quantification of 
BCL2/IGH tumor burden at diagnosis and the 
dynamic of its reduction with treatment with lower 
risk of contamination and higher inter-laboratory 
reproducibility. Conversely, RQ-PCR has lower 
sensitivity than nPCR, probably as less amount of 
DNA is tested, and it is more expensive and 
technically complex needing the construction of 
standard reference curves.
19
 
The occurrence of non-neoplastic BCL2/IGH 
rearrangements in the peripheral blood of healthy 
donors or patients without lymphoma was 
regarded as a possible confounder factor for MRD 
studies.
20,21
 The low chimeric gene levels found in 
non-FL patients and its clearance after 
chemotherapy, however, confirmed the feasibility 
of MRD testing in this setting.
22
 Another key point 
for the diffusion of MRD assessment is 
standardization of methodologies and definitions 
of common MRD terms. Standardization of RQ-
PCR, including data interpretation and reporting, 
has been made by the efforts of the European 
network project EURO-MRD and has been 
applied in clinical trials.
19,23-26
 New technical 
approaches could in the near future improve the 
frequency and the feasibility of BCL2/IGH 
rearrangements identification, as next generation 
sequencing (NGS) or droplet digital PCR.
27,28
 
  
Clinical Implication of Minimal Residual 
Disease Monitoring. Twenty-five years have 
passed since the first observations that MRD 
negativity plays a role in predicting the outcome of 
patients with FL.
13
 Early studies showed that 
standard chemotherapy programs can achieve a 
molecular remission (MR) in a minority of 
patients. First line anthracycline containing 
protocols could attain a MR in about 30-50% of 
the patients,
29,30
 while intensification with 
autologous stem-cell transplant (SCT) can lead up 
to 60-70% of MRD negativity.
31
 Conversely, the 
proportion was negligible in those with relapsed 
disease.
32
 In all of these studies, patients achieving 
a MR were characterized by a significantly 
prolonged disease control. Notably, long term 
results of two trials aiming at reducing neoplastic 
cell contamination before ASCT with ex vivo 
purging, confirmed that persistence of residual
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Figure 1. Diagram of breakpoint sites of the IGH/BCL2 translocation. In most cases the breakpoints of the IGH/BCL2 translocation are 
located downstream of the coding portion of the BCL2 gene and the IGH locus is mostly involved within the DJ recombination. In about 
50% of cases the breaks occur in a 150-bp region in the 3′ noncoding portion of the third exon of the BCL2 gene, named the major breakpoint 
region (MBR). The other less frequent breakpoints include the minor breakpoint region (mcr), the intermediate cluster region (icr),  the 3′ 
BCL2 and 5′ mcr regions accounting for 5-10%, 5-10%, 6% and 1% of the cases, respectively.15 
 
marrow involvement both at microscopic or 
molecular assessment were the only significant 
factors for long term remission, but not for 
survival.
33
 
The association of Rituximab with 
chemotherapy dramatically improved response 
rates, PFS and, most notably, OS of advanced FL 
patients requiring treatment.
34,35
 The ability of 
Rituximab to deplete FL neoplastic cells from 
peripheral blood and bone marrow, increased the 
rates of MR, accordingly. A clear demonstration 
of the Rituximab activity on MRD was shown in a 
study in which only responsive patients after 
CHOP therapy not achieving a MR were treated 
with 4 weekly infusion of Rituximab.
30
 Overall, 
sequential administration of CHOP followed by 
Rituximab resulted in complete BM and PB 
molecular response in more than 70% of patients. 
Freedom from recurrence at 3 years was 52-57% 
for those patients obtaining a durable MR after 
CHOP or CHOP plus Rituximab, while it was 
significantly lower (20%) for those failing to 
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obtain or lost a MR. Residual disease kinetic 
showed that most of the patients in MR after 
CHOP were negative at the first interim evaluation 
after 3 cycles. Conversely, a delayed maximum 
effect was noted after Rituximab, with 59%, 74% 
and 63% of the patients in MR at week +12, +28 
and +44 after treatment. This late effect of 
Rituximab was observed in other trials, as well as 
the more difficult clearance of MRD in the BM 
compared with the PB.
23,24
 Rituximab have been 
used as consolidation therapy after autologous 
SCT in small series of patients, and proved to be 
safe and effective both in increasing the quality of 
clinical response i.e. converting PR into CR, as 
well as in achieving MR.
36,37
 
The efficacy of front line Rituximab plus 
chemotherapy in inducing MR have been included 
as secondary end point in several large prospective 
trials (Table 1).  
In two different controlled studies, R-CHOP 
resulted in MR of 39-44%.
23,25
 Similar results 
were obtained with fludarabine and antracycline-
based induction regimens (R-FM, R-FND) and 
with mitoxantrone, chlorambucil, and 
prednisolone (R-MCP).
23,24,38
 Indirect evidence 
suggests that the less intensive regimen R-CVP 
could lead to inferior results both in term of 
clinical response and MR rates, explaining the 
shorter PFS observed compared to R-CHOP/R-
FM.
23
 Conversely, intensive regimens including 
upfront autologous SCT (R-HDS) increase the 
molecular response rates up to 80% of patients.
25
 
No data are currently available for the schema R-
Bendamustine in the front line setting, but 
Bendamustine alone or combined with the novel 
anti-CD20 monoclonal antibody Obinutuzumab in 
relapsed/refractory patients can induce MR.
39
 
Induction therapy with 90
Y
-Ibritumomab-Tiuxetan 
was associated with achievement of a MR in 
nearly all of the CR patients.
40
 Most importantly, 
all these trials confirmed the significant 
improvement in disease control in terms of PFS or 
relapse/event free survival in those patients 
achieving and maintaining the MR. The result was 
independent from other prognostic factors, most 
importantly the quality of response (CR vs PR), 
the chemotherapy induction regimen chosen and 
clinical risk factors as the FL prognostic index 
(FLIPI). However, the good results achieved in 
terms of disease control, did not translate in 
survival improvement. The importance of MR was 
shown also for a non-chemotherapy based 
consolidation. In a phase III trial 90
Y
-
Ibritumomab-Tiuxetan was randomly given as 
consolidation therapy after standard first line 
therapy.
41
 Interestingly, when compared to 
controls, consolidation with 90
Y
-Ibritumomab-
Tiuxetan did not improve the PFS of patients who 
already were in MR while a significant 
prolongation of PFS was obtained in MRD 
positive patients (38.4 vs 8.2 months of the control 
group, P<0.01). In the relapsed/refractory setting, 
a randomized phase III study comparing CHOP vs 
R-CHOP therapy with subsequent Rituximab 
maintenance vs observation further confirmed the 
predictive value of MR, as almost all of the few 
patients who were still BCL2/IgH PCR positive at 
the end of the 2 years of maintenance treatment 
relapsed rapidly.
42
 
Quantitative PCR methods have been used to 
measure the BCL2/IGH chimeric gene burden and 
early studies suggested that RQ-PCR evaluation 
before and after autologous transplantation may 
predict the clinical course of these patients.
43,44
 In 
a clinical trial evaluating the sequential 
administration of CHOP and Rituximab in MRD 
positive patients, a high lymphoma cell burden at 
diagnosis was associated with lower probability to 
achieve a clinical and molecular CR.
45
 The kinetic 
of BCL2/IGH positive cells during treatment 
showed that CHOP and Rituximab were both able 
to remove approximately 2 logs of tumor 
infiltration, thus explaining why patients with a 
limited lymphoma infiltration can achieve a 
molecular remission after CHOP chemotherapy 
alone, while the others necessitate the addition of 
Rituximab. Quantification of BCL2/IGH chimeric 
gene burden in the BM, but not in PB, was 
associated to a better event free survival. The 
result of the MRD analysis of a large phase III 
study confirmed the prognostic value of the 
molecular tumor burden both in term of likelihood 
to achieve a CR, and PFS.
23
 Of note, high 
lymphoma cell burden at diagnosis was 
independent from FLIPI and clinical response in 
determining PFS. The importance of RQ-PCR was 
additionally shown in a study in which significant 
reduction (>2 logs) of circulating lymphoma cells 
rather than the mere MRD negativity was 
associated with a favorable clinical response and 
prolonged event-free survival.
38
 However, not all 
the studies confirm these findings, probably due to 
the different induction regimen and Rituximab 
schedule.
24
 
 
www.mjhid.org Mediterr J Hematol Infect Dis 2017; 9; e2017010                                                                Pag. 5 / 8 
 
Table 1.  
 
N evaluated  
(% of enrolled) 
BCL2/IGH+ Source Treatment(s) ORR (CR) MRD negativity EFS/PFS (MRD – vs +) Notes 
Rambaldi et al., 
200230 
128 (100%) 100% BM and PB 
CHOP plus R in 
MRD+ 
94% (57%) 
32% after CHOP,  
74% after R 
3-year EFS:  
52% (after CHOP) 
57% (after CHOP+R) 
vs 20% 
P<0.001  
Ladetto et al., 
200825 
104 (78%) 70% BM 
R-CHOP vs  
R-HDS 
70% (62%) vs  
90% (85%) 
44% vs 80% 3-y PFS: 77% vs 33% P<0.001 Age 18-60, high risk 
Hirt et al., 
200838 
91 (45%) 47% PB MCP vs R-MCP 
72% (28%) vs 
100% (72%) 
0% vs 84% 
Median EFS:  
not reached vs 27 months 
P=0.02 
MRD- is considered a >2 log 
reduction of molecular 
burden 
Goff et al., 
200941 
414 (100%) 45% PB 
90Y-IT consolidation 
vs observation 
- 
90% vs 36% of 
previously MRD+ 
Median PFS:  
MRD+ at randomization:  
38 vs 8 months 
P<0.01 
Consolidation of responding 
patients after chemotherapy 
+/- R 
MRD- at randomization: 
37 vs 29 months 
P=NS 
Scholz et al., 
201240 
59 (100%) 49% 
PB and/or 
BM 
90Y-IT 87% (56%) 93% - - 
Age 50+, BM with <25% 
infiltration 
Ladetto et al., 
201324 
227 (97%) 51% BM 
R-FND plus R 
maintenance 
vs Observation 
86% (69%) 84% 
34-months PFS:  
72% vs 39% 
P=0.007 Age 60+ 
Galimberti et 
al., 201523 
415 (82%) 52% BM 
R-CVP vs  
R-CHOP vs R-FM 
88% (67%) vs 
93% (73%) vs 
91% (72%) 
25% vs 39%  
vs 36% 
(P=NS) 
3-year PFS: 
 64% vs 53% 
P=0.08  
Legend: ORR: overall response rate; MRD: minimal residual disease; CR: complete remission; EFS: event free survival; PFS: progression free survival; BM: bone marrow; PB: peripheral blood; R: 
Rituximab; CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone; HDS: high-dose sequential; MCP: mitoxantrone, chlorambucil and prednisolone; 90Y-IT: 90-Yttrium Ibritumomab 
Tiuxetan; FM: fludarabine, mitoxantrone; NS: not significant.
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Current Issues and Future Perspective. 
Compelling evidence indicates that MRD is a post 
treatment independent prognostic factor that can 
be consistently used to guide subsequent 
consolidation therapy in clinical trials. However a 
series of issues should be taken into consideration. 
Firstly, in large randomized prospective trials 
where molecular evaluation has been performed 
routinely, a molecular marker could be detected in 
only 50 to 60% of the patients.
23-25
 In a large study 
including samples from 415 patients, a molecular 
marker was present in 53% of the cases; in 
particular, 67.5% of patients without BM 
infiltration were MRD positive, conversely 17.6% 
of patients with microscopic marrow involvement 
at BMB were lacking the molecular marker.
23
 
Several reasons could explain this finding, mainly 
the presence of uncommon rearrangements and the 
lack of significant marrow involvement in patients 
with nodal disease.
15
 Despite the availability of 
primers and probes for detecting rare BCL2/IGH 
breakpoints will increase the cases with molecular 
marker, a significant proportion of patients are 
eventually excluded from this strategy. Persistence 
over time of MR is a major indication of sustained 
remission. As MRD detection is more informative 
on BM, especially in the Rituximab era, the need 
of multiple invasive procedures additionally limits 
the feasibility of MRD monitoring over time. 
Moreover, all the clinical trials reporting a 
prognostic implication of MR included the 
evaluation of response according to the 1999 or 
2007 International Working Group (IWG) criteria 
with the use of the sole contrast enhanced CT-
scan.
10,11
 The introduction of FDG-PET scan 
improved the accuracy of staging and response 
assessment in FDG-avid lymphomas and is 
currently recommended for the definition of 
response in FL.
46
 Several trials showed that 
concordance in CT-based and PET-based response 
designation is critical especially for patients in PR 
or CR unconfirmed, as PET scan is able to identify 
those patients with metabolically active disease 
and thus can improve the predictive value of 
response assessment.
47-49
 To date, no data is 
available regarding the integration of PET based 
response and MRD evaluation. The only report in 
this setting is a retrospective evaluation of a very 
limited proportion of patient (8%) enrolled in a 
prospective trial.
50
 This study suggests that PET 
and MRD are not strongly correlated with each 
other, and thus could be used as complementary 
techniques at the end of therapy to optimally 
explore the nodal and bone marrow compartments, 
but further studies are necessary to confirm the 
independent role of the two techniques. 
The current clinical significance of MRD 
evaluation should also be evaluated when 
considering the evolving scenario of FL treatment. 
To date, given the satisfactory median results of 
chemo-immunotherapy and the lack of a survival 
impact of the chemotherapies available, the 
routine selection of induction treatment is guided 
more from the avoidance of unnecessary toxicity 
rather than the mere activity of the regimen.
1
  
However, while most patients achieve a prolonged 
disease control, a sizeable subset of cases remains 
substantially refractory to front line treatment with 
a poor prognosis.
9
 Clinical scores currently 
available as FLIPI or FLIPI2 fail in identifying 
such cases, and a growing numbers of prognostic 
factors before or after treatment have been 
developed with this aim.
9,51-53
 Thus, definition of 
high risk patient and, accordingly, end points for 
clinical trials are changing. Treatment results are 
satisfactory in low risk patients and integration of 
new molecules should be made with great caution 
in this group.
54
 In this regard, achievement of 
sustained MR could allow the de-escalation of 
standard therapy in very low risk patients i.e. 
maintenance with Rituximab. Conversely, high 
risk patients are a group for which standard 
treatment need to be implemented and PFS should 
not represent per se the primary end point. Efforts 
to consistently characterize this latter group are 
ongoing and surrogate end points for survival as 2-
year PFS have been proposed.
9,51-53
 
 
Conclusion. Although not yet integrated in 
clinical practice as compared to other setting such 
acute lymphoblastic leukemia,
55
 MRD evaluation 
is commonly integrated in clinical trials testing the 
efficacy of new treatment protocols in FL patients. 
In this setting MRD maintains its consistent and 
independent prognostic significance. Achievement 
of MR is a marker of treatment sensibility that has 
been associated with good clinical outcome in 
term of PFS, but not OS, independently from the 
specific therapy. Some technical limitations such 
as the limited coverage of the different breakpoints 
present in the BCL2/IgH rearrangements will be 
likely overcome in the near future by more 
appropriate molecular approaches.
27,28
 These 
laboratory improvements, most likely in 
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combination with the new imaging technologies 
currently tested by an ongoing clinical trial 
(NCT02063685), will probably lead to a 
reappraisal of MRD evaluation in FL patients  
 
References:  
1. Kahl BS, Yang DT. Follicular lymphoma: evolving therapeutic 
strategies. Blood. 2016;127:2055-2063. 
https://doi.org/10.1182/blood-2015-11-624288    PMid:26989204    
2. Tan D, Horning SJ, Hoppe RT, et al. Improvements in observed 
and relative survival in follicular grade 1-2 lymphoma during 4 
decades: the Stanford University experience. Blood. 2013;122:981-
987. https://doi.org/10.1182/blood-2013-03-491514    
PMid:23777769      PMCid:PMC3739040 
3. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-
burden follicular lymphomas between an initial no-treatment 
policy, prednimustine, or interferon alfa: a randomized study from 
the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude 
des Lymphomes de l'Adulte. J Clin Oncol. 1997;15:1110-1117.   
PMid:9060552    
4. Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a 
watch and wait policy versus immediate systemic treatment for 
asymptomatic advanced-stage non-Hodgkin lymphoma: a 
randomised controlled trial. Lancet. 2003;362:516-522. 
https://doi.org/10.1016/S0140-6736(03)14110-4  
5. Solal-Celigny P, Bellei M, Marcheselli L, et al. Watchful waiting 
in low-tumor burden follicular lymphoma in the rituximab era: 
results of an F2-study database. J Clin Oncol. 2012;30:3848-3853. 
https://doi.org/10.1200/JCO.2010.33.4474    PMid:23008294    
6. Hiddemann W, Cheson BD. How we manage follicular lymphoma. 
Leukemia. 2014;28:1388-1395. https://doi.org/10.1038/leu.2014.91    
PMid:24577532    
7. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 
years in patients with high tumour burden follicular lymphoma 
responding to rituximab plus chemotherapy (PRIMA): a phase 3, 
randomised controlled trial. Lancet. 2011;377:42-51. 
https://doi.org/10.1016/S0140-6736(10)62175-7  
8. Barta SK, Li H, Hochster HS, et al. Randomized phase 3 study in 
low-grade lymphoma comparing maintenance anti-CD20 antibody 
with observation after induction therapy: A trial of the ECOG-
ACRIN Cancer Research Group (E1496). Cancer. 2016;122:2996-
3004. https://doi.org/10.1002/cncr.30137    PMid:27351685    
9. Tarella C, Gueli A, Delaini F, et al. Rate of primary refractory 
disease in B and T-cell non-Hodgkin's lymphoma: correlation with 
long-term survival. PLoS One. 2014;9:e106745. 
https://doi.org/10.1371/journal.pone.0106745    PMid:25255081      
PMCid:PMC4177839 
10. Cheson BD, Horning SJ, Coiffier B, et al. Report of an 
international workshop to standardize response criteria for non-
Hodgkin's lymphomas. NCI Sponsored International Working 
Group. J Clin Oncol. 1999;17:1244.   PMid:10561185    
11. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria 
for malignant lymphoma. J Clin Oncol. 2007;25:579-586. 
https://doi.org/10.1200/JCO.2006.09.2403    PMid:17242396    
12. Vaandrager JW, Schuuring E, Raap T, Philippo K, Kleiverda K, 
Kluin P. Interphase FISH detection of BCL2 rearrangement in 
follicular lymphoma using breakpoint-flanking probes. Genes 
Chromosomes Cancer. 2000;27:85-94. 
https://doi.org/10.1002/(SICI)1098-2264(200001)27:1<85::AID-
GCC11>3.0.CO;2-9  
13. Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging 
of marrow assessed by PCR before autologous bone marrow 
transplantation for B-cell lymphoma. N Engl J Med. 
1991;325:1525-1533. 
https://doi.org/10.1056/NEJM199111283252201    PMid:1944436    
14. Basso K, Dalla-Favera R. Germinal centres and B cell 
lymphomagenesis. Nat Rev Immunol. 2015;15:172-184. 
https://doi.org/10.1038/nri3814    PMid:25712152    
15. Weinberg OK, Ai WZ, Mariappan MR, Shum C, Levy R, Arber 
DA. ''Minor'' BCL2 breakpoints in follicular lymphoma: frequency 
and correlation with grade and disease presentation in 236 cases. J 
Mol Diagn. 2007;9:530-537. 
https://doi.org/10.2353/jmoldx.2007.070038    PMid:17652637      
PMCid:PMC1975105 
16. Weiss LM, Warnke RA, Sklar J, Cleary ML. Molecular analysis of 
the t(14;18) chromosomal translocation in malignant lymphomas. 
N Engl J Med. 1987;317:1185-1189. 
https://doi.org/10.1056/NEJM198711053171904    PMid:3657890    
17. Holland PM, Abramson RD, Watson R, Gelfand DH. Detection of 
specific polymerase chain reaction product by utilizing the 5'----3' 
exonuclease activity of Thermus aquaticus DNA polymerase. Proc 
Natl Acad Sci U S A. 1991;88:7276-7280. 
https://doi.org/10.1073/pnas.88.16.7276    PMid:1871133      
PMCid:PMC52277 
18. Donovan JW, Ladetto M, Zou G, et al. Immunoglobulin heavy-
chain consensus probes for real-time PCR quantification of residual 
disease in acute lymphoblastic leukemia. Blood. 2000;95:2651-
2658.   PMid:10753847    
19. Bruggemann M, Schrauder A, Raff T, et al. Standardized MRD 
quantification in European ALL trials: proceedings of the Second 
International Symposium on MRD assessment in Kiel, Germany, 
18-20 September 2008. Leukemia. 2010;24:521-535. 
https://doi.org/10.1038/leu.2009.268    PMid:20033054    
20. Summers KE, Goff LK, Wilson AG, Gupta RK, Lister TA, 
Fitzgibbon J. Frequency of the Bcl-2/IgH rearrangement in normal 
individuals: implications for the monitoring of disease in patients 
with follicular lymphoma. J Clin Oncol. 2001;19:420-424.   
PMid:11208834    
21. Dolken G, Dolken L, Hirt C, Fusch C, Rabkin CS, Schuler F. Age-
dependent prevalence and frequency of circulating t(14;18)-
positive cells in the peripheral blood of healthy individuals. J Natl 
Cancer Inst Monogr. 2008:44-47. 
https://doi.org/10.1093/jncimonographs/lgn005    PMid:18648002    
22. Ladetto M, Drandi D, Compagno M, et al. PCR-detectable 
nonneoplastic Bcl-2/IgH rearrangements are common in normal 
subjects and cancer patients at diagnosis but rare in subjects treated 
with chemotherapy. J Clin Oncol. 2003;21:1398-1403. 
https://doi.org/10.1200/JCO.2003.07.070    PMid:12663733    
23. Galimberti S, Luminari S, Ciabatti E, et al. Minimal residual 
disease after conventional treatment significantly impacts on 
progression-free survival of patients with follicular lymphoma: the 
FIL FOLL05 trial. Clin Cancer Res. 2014;20:6398-6405. 
https://doi.org/10.1158/1078-0432.CCR-14-0407    
PMid:25316810    
24. Ladetto M, Lobetti-Bodoni C, Mantoan B, et al. Persistence of 
minimal residual disease in bone marrow predicts outcome in 
follicular lymphomas treated with a rituximab-intensive program. 
Blood. 2013;122:3759-3766. https://doi.org/10.1182/blood-2013-
06-507319    PMid:24085766    
25. Ladetto M, De Marco F, Benedetti F, et al. Prospective, multicenter 
randomized GITMO/IIL trial comparing intensive (R-HDS) versus 
conventional (CHOP-R) chemoimmunotherapy in high-risk 
follicular lymphoma at diagnosis: the superior disease control of R-
HDS does not translate into an overall survival advantage. Blood. 
2008;111:4004-4013. https://doi.org/10.1182/blood-2007-10-
116749    PMid:18239086    
26. van der Velden VH, Cazzaniga G, Schrauder A, et al. Analysis of 
minimal residual disease by Ig/TCR gene rearrangements: 
guidelines for interpretation of real-time quantitative PCR data. 
Leukemia. 2007;21:604-611. 
https://doi.org/10.1038/sj.leu.2404586  
27. Drandi D, Kubiczkova-Besse L, Ferrero S, et al. Minimal Residual 
Disease Detection by Droplet Digital PCR in Multiple Myeloma, 
Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison 
with Real-Time PCR. J Mol Diagn. 2015;17:652-660. 
https://doi.org/10.1016/j.jmoldx.2015.05.007    PMid:26319783    
28. Kotrova M, Muzikova K, Mejstrikova E, et al. The predictive 
strength of next-generation sequencing MRD detection for relapse 
compared with current methods in childhood ALL. Blood. 
2015;126:1045-1047. https://doi.org/10.1182/blood-2015-07-
655159    PMid:26294720      PMCid:PMC4551355 
29. Lopez-Guillermo A, Cabanillas F, McLaughlin P, et al. The 
clinical significance of molecular response in indolent follicular 
lymphomas. Blood. 1998;91:2955-2960.   PMid:9531606    
30. Rambaldi A, Lazzari M, Manzoni C, et al. Monitoring of minimal 
residual disease after CHOP and rituximab in previously untreated 
patients with follicular lymphoma. Blood. 2002;99:856-862. 
https://doi.org/10.1182/blood.V99.3.856    PMid:11806987    
 
www.mjhid.org Mediterr J Hematol Infect Dis 2017; 9; e2017010                                                                Pag. 8 / 8 
 
31. Ladetto M, Corradini P, Vallet S, et al. High rate of clinical and 
molecular remissions in follicular lymphoma patients receiving 
high-dose sequential chemotherapy and autografting at diagnosis: a 
multicenter, prospective study by the Gruppo Italiano Trapianto 
Midollo Osseo (GITMO). Blood. 2002;100:1559-1565. 
https://doi.org/10.1182/blood-2002-02-0621    PMid:12176870    
32. Gribben JG, Freedman A, Woo SD, et al. All advanced stage non-
Hodgkin's lymphomas with a polymerase chain reaction 
amplifiable breakpoint of bcl-2 have residual cells containing the 
bcl-2 rearrangement at evaluation and after treatment. Blood. 
1991;78:3275-3280.   PMid:1742487    
33. Brown JR, Feng Y, Gribben JG, et al. Long-term survival after 
autologous bone marrow transplantation for follicular lymphoma in 
first remission. Biol Blood Marrow Transplant. 2007;13:1057-
1065. https://doi.org/10.1016/j.bbmt.2007.05.012    
PMid:17697968      PMCid:PMC4147857 
34. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with 
rituximab added to the combination of cyclophosphamide, 
doxorubicin, vincristine, and prednisone (CHOP) significantly 
improves the outcome for patients with advanced-stage follicular 
lymphoma compared with therapy with CHOP alone: results of a 
prospective randomized study of the German Low-Grade 
Lymphoma Study Group. Blood. 2005;106:3725-3732. 
https://doi.org/10.1182/blood-2005-01-0016    PMid:16123223    
35. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus 
rituximab compared with CVP as first-line treatment for advanced 
follicular lymphoma. Blood. 2005;105:1417-1423. 
https://doi.org/10.1182/blood-2004-08-3175    PMid:15494430    
36. Brugger W, Hirsch J, Grunebach F, et al. Rituximab consolidation 
after high-dose chemotherapy and autologous blood stem cell 
transplantation in follicular and mantle cell lymphoma: a 
prospective, multicenter phase II study. Ann Oncol. 2004;15:1691-
1698. https://doi.org/10.1093/annonc/mdh425    PMid:15520073    
37. Morschhauser F, Recher C, Milpied N, et al. A 4-weekly course of 
rituximab is safe and improves tumor control for patients with 
minimal residual disease persisting 3 months after autologous 
hematopoietic stem-cell transplantation: results of a prospective 
multicenter phase II study in patients with follicular lymphoma. 
Ann Oncol. 2012;23:2687-2695. 
https://doi.org/10.1093/annonc/mds202    PMid:22767588    
38. Hirt C, Schuler F, Kiefer T, et al. Rapid and sustained clearance of 
circulating lymphoma cells after chemotherapy plus rituximab: 
clinical significance of quantitative t(14;18) PCR monitoring in 
advanced stage follicular lymphoma patients. Br J Haematol. 
2008;141:631-640. https://doi.org/10.1111/j.1365-
2141.2008.07101.x    PMid:18422779    
39. Pott C, Belada D, Danesi N, et al. Analysis of Minimal Residual 
Disease in Follicular Lymphoma Patients in Gadolin, a Phase III 
Study of Obinutuzumab Plus Bendamustine Versus Bendamustine 
in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. Blood. 
2015;126:2015-2012-2003 2016:2028:2015. 
40. Scholz CW, Pinto A, Linkesch W, et al. (90)Yttrium-ibritumomab-
tiuxetan as first-line treatment for follicular lymphoma: 30 months 
of follow-up data from an international multicenter phase II clinical 
trial. J Clin Oncol. 2012;31:308-313. 
https://doi.org/10.1200/JCO.2011.41.1553    PMid:23233718    
41. Goff L, Summers K, Iqbal S, et al. Quantitative PCR analysis for 
Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan 
as consolidation of first remission in patients with follicular 
lymphoma. J Clin Oncol. 2009;27:6094-6100. 
https://doi.org/10.1200/JCO.2009.22.6258    PMid:19858392    
42. van Oers MH, Tonnissen E, Van Glabbeke M, et al. BCL-2/IgH 
polymerase chain reaction status at the end of induction treatment 
is not predictive for progression-free survival in relapsed/resistant 
follicular lymphoma: results of a prospective randomized EORTC 
20981 phase III intergroup study. J Clin Oncol. 2010;28:2246-
2252. https://doi.org/10.1200/JCO.2009.25.0852    PMid:20368567    
43. Ladetto M, Sametti S, Donovan JW, et al. A validated real-time 
quantitative PCR approach shows a correlation between tumor 
burden and successful ex vivo purging in follicular lymphoma 
patients. Exp Hematol. 2001;29:183-193. 
https://doi.org/10.1016/S0301-472X(00)00651-2  
44. Galimberti S, Guerrini F, Morabito F, et al. Quantitative molecular 
evaluation in autotransplant programs for follicular lymphoma: 
efficacy of in vivo purging by Rituximab. Bone Marrow 
Transplant. 2003;32:57-63. https://doi.org/10.1038/sj.bmt.1704102    
PMid:12815479    
45. Rambaldi A, Carlotti E, Oldani E, et al. Quantitative PCR of bone 
marrow BCL2/IgH+ cells at diagnosis predicts treatment response 
and long-term outcome in follicular non-Hodgkin lymphoma. 
Blood. 2005;105:3428-3433. https://doi.org/10.1182/blood-2004-
06-2490    PMid:15637137    
46. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for 
initial evaluation, staging, and response assessment of Hodgkin and 
non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 
2014;32:3059-3068. https://doi.org/10.1200/JCO.2013.54.8800    
PMid:25113753      PMCid:PMC4979083 
47. Le Dortz L, De Guibert S, Bayat S, et al. Diagnostic and prognostic 
impact of 18F-FDG PET/CT in follicular lymphoma. Eur J Nucl 
Med Mol Imaging. 2010;37:2307-2314. 
https://doi.org/10.1007/s00259-010-1539-5    PMid:20717826    
48. Dupuis J, Berriolo-Riedinger A, Julian A, et al. Impact of 
[(18)F]fluorodeoxyglucose positron emission tomography response 
evaluation in patients with high-tumor burden follicular lymphoma 
treated with immunochemotherapy: a prospective study from the 
Groupe d'Etudes des Lymphomes de l'Adulte and GOELAMS. J 
Clin Oncol. 2012;30:4317-4322. 
https://doi.org/10.1200/JCO.2012.43.0934    PMid:23109699    
49. Trotman J, Fournier M, Lamy T, et al. Positron emission 
tomography-computed tomography (PET-CT) after induction 
therapy is highly predictive of patient outcome in follicular 
lymphoma: analysis of PET-CT in a subset of PRIMA trial 
participants. J Clin Oncol. 2011;29:3194-3200. 
https://doi.org/10.1200/JCO.2011.35.0736    PMid:21747087    
50. Luminari S, Galimberti S, Versari A, et al. Positron emission 
tomography response and minimal residual disease impact on 
progression-free survival in patients with follicular lymphoma. A 
subset analysis from the FOLL05 trial of the Fondazione Italiana 
Linfomi. Haematologica. 2016;101:e66-68. 
https://doi.org/10.3324/haematol.2015.132811    PMid:26471485      
PMCid:PMC4938338 
51. Casulo C, Byrtek M, Dawson KL, et al. Early Relapse of Follicular 
Lymphoma After Rituximab Plus Cyclophosphamide, 
Doxorubicin, Vincristine, and Prednisone Defines Patients at High 
Risk for Death: An Analysis From the National LymphoCare 
Study. J Clin Oncol. 2015;33:2516-2522. 
https://doi.org/10.1200/JCO.2014.59.7534    PMid:26124482      
PMCid:PMC4879714 
52. Pastore A, Jurinovic V, Kridel R, et al. Integration of gene 
mutations in risk prognostication for patients receiving first-line 
immunochemotherapy for follicular lymphoma: a retrospective 
analysis of a prospective clinical trial and validation in a 
population-based registry. Lancet Oncol. 2015;16:1111-1122. 
https://doi.org/10.1016/S1470-2045(15)00169-2  
53. Jurinovic V, Kridel R, Staiger AM, et al. Clinicogenetic risk 
models predict early progression of follicular lymphoma after first-
line immunochemotherapy. Blood. 2016;128:1112-1120. 
https://doi.org/10.1182/blood-2016-05-717355    PMid:27418643   
54. Cheson BD. Speed bumps on the road to a chemotherapy-free 
world for lymphoma patients. Blood. 2016;128:325-330. 
https://doi.org/10.1182/blood-2016-04-709477   PMid:27222479    
55. Spinelli O, Tosi M, Peruta B, et al. Prognostic significance and 
treatment implications of minimal residual disease studies in 
Philadelphia-negative adult acute lymphoblastic leukemia. 
Mediterr J Hematol Infect Dis. 2014;6:e2014062. 
https://doi.org/10.4084/mjhid.2014.062    PMid:25237475      
PMCid:PMC4165493
 
 
